Loading…
Theriva Biologics, Inc. is projected to decline to $0.2535 by 2027, a -14% move from its current price of $0.2943. TOVX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.2773 | $0.2942 | $0.3122 | -0.02% |
| May 30 | $0.2706 | $0.2942 | $0.3199 | -0.04% |
| May 31 | $0.2655 | $0.2941 | $0.3259 | -0.06% |
| Jun 1 | $0.2612 | $0.294 | $0.331 | -0.09% |
| Jun 2 | $0.2575 | $0.294 | $0.3356 | -0.11% |
| Jun 3 | $0.2543 | $0.2939 | $0.3398 | -0.13% |
| Jun 4 | $0.2513 | $0.2939 | $0.3437 | -0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.2513 | $0.2939 | $0.3437 | -0.15% |
| Week 2 | $0.2351 | $0.2934 | $0.3661 | -0.30% |
| Week 3 | $0.2234 | $0.293 | $0.3842 | -0.45% |
| Week 4 | $0.2139 | $0.2925 | $0.4001 | -0.60% |
| Week 5 | $0.2058 | $0.2921 | $0.4145 | -0.75% |
| Week 6 | $0.1988 | $0.2917 | $0.428 | -0.90% |
| Week 7 | $0.1925 | $0.2912 | $0.4407 | -1.05% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Theriva Biologics, Inc. is a clinical-stage healthcare company focused on developing therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate is VCN-01 (zabilugene almadenorepvec), a clinical-stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc.
to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc.
is headquartered in Rockville, Maryland.
Theriva Biologics, Inc. is a clinical-stage healthcare company focused on developing therapeutics to treat cancer and related diseases in the United States. It is headquartered in Rockville, Maryland.
The stock trades with a current price of $0.314 and a market cap of $14.41M, placing it with rank 5046.
The price outlook shows a path from near-term neutral levels toward higher prices over the forecast horizon, with 2026 centered around a $0.314 avg and long-run upside in the 2030s–2050s as indicated by the year-by-year forecast. For 2030 the avg is $0.3217 with a max of $0.5611 and a positive 2.4% ROI, extending into 2031–2050 with bullish sentiment and substantial upside.
A major floor 46.8% below — a decisive break under it would weaken the trend.
The nearest floor, 15.1% below — buyers have tended to step in here.
The nearest ceiling, 39.3% above — a clean break opens room to run.
A major ceiling 62.0% above — clearing it would confirm fresh momentum.
Key TOVX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TOVX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.30 | Sell | $0.2979 | Sell |
| MA 10 | $0.301 | Sell | $0.3053 | Sell |
| MA 20 | $0.33 | Sell | $0.313 | Sell |
| MA 50 | $0.288 | Buy | $0.2933 | Buy |
| MA 100 | $0.2425 | Buy | $0.2824 | Buy |
| MA 200 | $0.2908 | Buy | $0.4728 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.22 | Neutral |
| Stoch RSI (14) | 26.62 | Neutral |
| CCI (20) | -88.89 | Neutral |
| Williams %R (14) | -77.78 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -17.14 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 22.22 | Neutral |
| TRIX (15) | 0.28 | Buy |
| Awesome (5,34) | -0.02 | Sell |
| Ultimate (7,14,28) | 44.34 | Neutral |
| Momentum (10) | -0.03 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 0.30 | Sell |
| ADX (14) | 12.84 | Neutral |
| ATR (14) | 0.02 | Info |
The 30-day technical picture for Theriva Biologics is Neutral. The RSI14 is 50, and the stock trades around the neutral zone.
The stock’s short-term trend is supported by the SMA50 at $0.2836 and the SMA200 at $0.2917. These moving averages suggest a tight range around the current price and no clear trend yet.
The immediate support is at $0.24 and the resistance at $0.41. The 30-day range runs from a low of $0.2081 to a high of $0.4739, indicating a modestly wide recent trading band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.18 | $0.2943 | $0.3719 | 0% | Neutral | |
| $0.1824 | $0.2535 | $0.3812 | -14% | Neutral | |
| $0.1759 | $0.2594 | $0.4147 | -12% | Neutral | |
| $0.1581 | $0.2455 | $0.4114 | -17% | Bearish | |
| $0.178 | $0.2895 | $0.5048 | -2% | Neutral | |
| $0.2108 | $0.3582 | $0.6461 | +22% | Bullish | |
| $0.2316 | $0.4105 | $0.7631 | +39% | Bullish | |
| $0.2199 | $0.4058 | $0.7751 | +38% | Bullish | |
| $0.1828 | $0.3508 | $0.6869 | +19% | Neutral | |
| $0.1773 | $0.3538 | $0.7085 | +20% | Bullish | |
| $0.2604 | $0.5787 | $1.27 | +97% | Bullish | |
| $0.3203 | $0.7117 | $1.64 | +142% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.18 | $0.2943 | $0.3469 | +0.00% |
| June 2026 | $0.232 | $0.2782 | $0.3457 | -5.47% |
| July 2026 | $0.2366 | $0.2886 | $0.3678 | +3.74% |
| August 2026 | $0.2414 | $0.2983 | $0.3876 | +3.37% |
| September 2026 | $0.2257 | $0.2821 | $0.3723 | -5.44% |
| October 2026 | $0.2148 | $0.2712 | $0.3629 | -3.87% |
| November 2026 | $0.2191 | $0.2792 | $0.3781 | +2.95% |
| December 2026 | $0.2112 | $0.2714 | $0.3719 | -2.76% |
Click any year to see its month-by-month TOVX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect TOVX to range from $0.18 to $0.3719 through 2026. The $0.2943 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The TOVX price prediction for 2027 points to an average of $0.2535 (low $0.1824, high $0.3812) — a potential decline of -14% on today's $0.2943. A consolidation phase looks the most probable path here.
In 2028, TOVX is projected to trade between $0.1759 and $0.4147, averaging $0.2594 — a potential decline of -12% from today's $0.2943. That is up +2% on the projected 2027 average. Price action looks broadly range-bound.
Theriva Biologics, Inc.'s 2029 outlook centres on $0.2455, within a $0.1581 to $0.4114 range. That is -5% versus the projected 2028 average. That marks a -17% change versus current levels. Expect choppier, lower action through this leg of the cycle.
By 2030, TOVX could reach as high as $0.5048, with a base case around $0.2895 and support toward $0.178 — roughly -2% from $0.2943. Price action looks broadly range-bound.
Expect TOVX to range from $0.2108 to $0.6461 through 2031. The $0.3582 average target implies a +22% move from current prices. That is up +24% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The TOVX price prediction for 2032 points to an average of $0.4105 (low $0.2316, high $0.7631) — a potential gain of +39% on today's $0.2943. Momentum favours further upside here.
In 2033, TOVX is projected to trade between $0.2199 and $0.7751, averaging $0.4058 — a potential gain of +38% from today's $0.2943. That is -1% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Theriva Biologics, Inc.'s 2034 outlook centres on $0.3508, within a $0.1828 to $0.6869 range. That is -14% versus the projected 2033 average. That marks a +19% change versus current levels. Price action looks broadly range-bound.
By 2035, TOVX could reach as high as $0.7085, with a base case around $0.3538 and support toward $0.1773 — roughly +20% from $0.2943. Buyers look set to stay in control over this stretch.
Expect TOVX to range from $0.2604 to $1.27 through 2040. The $0.5787 average target implies a +97% move from current prices. That is up +64% on the projected 2035 average. Momentum favours further upside here.
The TOVX price prediction for 2050 points to an average of $0.7117 (low $0.3203, high $1.64) — a potential gain of +142% on today's $0.2943. Buyers look set to stay in control over this stretch.
Investing $1,000 in TOVX today (≈ 3,397.893306 TOVX) could be worth
$2,418.4
+$1,418.4 (+142%) by 2050 · US Dollar
Based on the average projected TOVX price of $0.71 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TOVXwould be worth at today's price.
$1,000 invested in TOVX on May 27, 2025 (≈ 2,325.581357 TOVX) would be worth
$684.42
-$315.58 (-31.6%) today · 0.68× · US Dollar
Based on a TOVX entry price of $0.43 vs. today's $0.2943.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.3 | $981 | -1.9% |
| 1 month ago | $0.35 | $840.86 | -15.9% |
| 3 months ago | $0.2 | $1,471.5 | +47.1% |
| 6 months ago | $0.27 | $1,090 | +9.0% |
| 1 year ago | $0.43 | $684.42 | -31.6% |
| All time (5.0y) ago | $127.5 | $2.31 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TOVX forecast.
Our base-case forecast reaches $0.59 around 2050.
Implied market cap at $0.59: $27.08M
The multi-year forecast shows a shift from neutral to bullish sentiment beginning in the early 2030s and continuing through 2050 and beyond. The 2030 forecast yields an avg of $0.3217 with a max of $0.5611 and a 2.4% ROI, signaling limited near-term upside.
From 2031 onward, sentiment turns bullish with a 2031 avg of $0.4022 and ROI of 28.1%, rising further to 2032 avg $0.4477 (ROI 42.6%), and 2033 avg $0.4464 (ROI 42.2%). The 2040 forecast shows an avg of $0.6493 with a ROI of 106.8%, and the 2050 forecast carries an avg of $0.7955 with a ROI of 153.3%.
These projections imply meaningful longer-term upside despite near-term volatility, but they are estimates and not guarantees. Risks include variability in clinical progress, regulatory outcomes, and market conditions that could alter the path to the higher price levels.
Tap a question to reveal the answer.
2030 — min $0.1976, avg $0.3217, max $0.5611; ROI 2.4%; sentiment NEUTRAL.
Near-term bears are indicated with 2029 having min $0.17, avg $0.264, max $0.4428 and ROI -15.9% (sentiment BEARISH). From 2031 onward, forecasts turn bullish with rising averages (e.g., 2031 avg $0.4022, ROI 28.1%), suggesting potential upside but with high risk and no guarantees.
Yes. The 30-day resistance is $0.41, and forecasted max prices exceed that level: 2030 max $0.5611, 2032 max $0.8325, 2033 max $0.853, 2040 max $1.43, and 2050 max $1.83.
The 30-day range is from $0.2081 to $0.4739.
Current price: $0.314. Market cap: $14.41M.
Theriva Biologics, Inc. Community Discussion
0Share your Theriva Biologics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.